--- title: "Precision BioSciences (DTIL) news: offering" url: "https://aibio.space/companies/precision-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "DTIL offering news: Precision BioSciences prices $75,000,093 stock and warrant offering. Precision BioSciences, Inc. (NASDAQ: DTIL), United States." --- DTIL Precision BioSciences, Inc. NASDAQ · United States # Precision BioSciences (DTIL) news DTIL offering news Debt Financing · 2026-06-10 ## [Precision BioSciences extends Banc of California term loan](https://aibio.space/news/precision-biosciences-extends-banc-california-term-loan/) Precision BioSciences has moved the maturity of its Banc of California term loan from June 30, 2027 to December 31, 2029. The company used $65.8 million in operations in 2025 and ended 2024 with $85.9 million in cash and cash equivalents. ## Latest Precision BioSciences news 1. 2025-11-12 Financings [Precision BioSciences prices $75,000,093 stock and warrant offering](https://aibio.space/news/precision-biosciences-prices-75-000-093-stock-warrant-offering/) Guggenheim Securities, LLC is the sole underwriter. The company sells 10,815,000 shares, each with half a warrant, at a combined $6.14. Proceeds are $70,500,087 before expenses, and the as adjusted net tangible book value would be $3.74 a share. 2. 2025-03-26 Financings [Precision BioSciences updates its stock sales limit to $14,868,926](https://aibio.space/news/precision-biosciences-updates-stock-sales-limit-14-868-926/) Precision BioSciences, Inc. became subject to a one-third-of-float cap on shelf offerings on March 26, 2025, when it filed its 2024 annual report. It filed a supplement to its Jefferies at-the-market program to reflect that. ## Precision BioSciences at a glance - **Ticker**: DTIL - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $87.5 million ### Related companies - [Atrium Therapeutics](https://aibio.space/companies/atrium-therapeutics/) NASDAQ: RNA - [NeOnc Technologies Holdings](https://aibio.space/companies/neonc-technologies/) NASDAQ: NTHI - [Sionna Therapeutics](https://aibio.space/companies/sionna-therapeutics/) NASDAQ: SION - [INmune Bio](https://aibio.space/companies/inmune-bio/) NASDAQ: INMB - [CG Oncology](https://aibio.space/companies/cg-oncology/) NASDAQ: CGON - [Aldeyra Therapeutics](https://aibio.space/companies/aldeyra-therapeutics/) NASDAQ: ALDX - [Oncotelic Therapeutics](https://aibio.space/companies/oncotelic-therapeutics/) OTC: OTLC - [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) NASDAQ: DMAC ### Also on NASDAQ - [20/20 Biolabs](https://aibio.space/companies/20-20-biolabs/) AIDX - [Heartflow](https://aibio.space/companies/heartflow/) HTFL - [Solid Biosciences](https://aibio.space/companies/solid-biosciences/) SLDB - [Organogenesis Holdings](https://aibio.space/companies/organogenesis/) ORGO - [Kyverna Therapeutics](https://aibio.space/companies/kyverna-therapeutics/) KYTX - [Advanced Biomed](https://aibio.space/companies/advanced-biomed/) ADVB ## Precision BioSciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$54.2 million](https://www.sec.gov/Archives/edgar/data/1357874/000162828026017019/) | [$59.6 million](https://www.sec.gov/Archives/edgar/data/1357874/000162828026017019/) | | Net income (loss) | [-$45.7 million](https://www.sec.gov/Archives/edgar/data/1357874/000162828026017019/) | [$7.2 million](https://www.sec.gov/Archives/edgar/data/1357874/000162828026017019/) | | Cash from operations | [-$65.8 million](https://www.sec.gov/Archives/edgar/data/1357874/000162828026017019/) | [-$58.4 million](https://www.sec.gov/Archives/edgar/data/1357874/000162828026017019/) | | Cash and equivalents | [$110.8 million](https://www.sec.gov/Archives/edgar/data/1357874/000162828026053837/) | [$85.9 million](https://www.sec.gov/Archives/edgar/data/1357874/000162828026017019/) | | Short-term investments | [$4.8 million](https://www.sec.gov/Archives/edgar/data/1357874/000162828026053837/) | [$413,000](https://www.sec.gov/Archives/edgar/data/1357874/000162828026017019/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $86.1 million, plus short-term investments of $1.5 million, $87.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Precision BioSciences Has Precision BioSciences raised money recently? Our latest story on this, dated Nov 12, 2025: "Precision BioSciences prices $75,000,093 stock and warrant offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/precision-biosciences-prices-75-000-093-stock-warrant-offering/). What is the ticker symbol of Precision BioSciences? Precision BioSciences, Inc. trades under the ticker DTIL on NASDAQ. Where is Precision BioSciences listed? Precision BioSciences, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:PBS0. What is the SEC CIK of Precision BioSciences? The SEC Central Index Key (CIK) for Precision BioSciences, Inc. is 1357874. Its filings are on SEC EDGAR. How many shares does Precision BioSciences have outstanding? 27,601,554 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Precision BioSciences listed under? Our directory records Precision BioSciences, Inc. under United States. What does Precision BioSciences do? Our directory classifies Precision BioSciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Precision BioSciences? The ISIN recorded for Precision BioSciences, Inc. is US74019P2074. Does aibio.space cover Precision BioSciences? aibio.space lists Precision BioSciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Precision BioSciences incorporated? SEC records list its state or country of incorporation as DE. Is Precision BioSciences profitable? Precision BioSciences, Inc. reported a net loss of $45.7 million for the fiscal year ended Dec 31, 2025, and used $65.8 million of cash in operations, per its annual report to the SEC. How much does Precision BioSciences spend on research and development? $54.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Precision BioSciences have? $87.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Precision BioSciences (DTIL) stock news? Our latest story on Precision BioSciences, dated Jun 10, 2026: "Precision BioSciences extends Banc of California term loan". Precision BioSciences has moved the maturity of its Banc of California term loan from June 30, 2027 to December 31, 2029. The company used $65.8 million in operations in 2025 and ended 2024 with $85.9 million in cash and cash equivalents. [Source](https://aibio.space/news/precision-biosciences-extends-banc-california-term-loan/). Does Precision BioSciences have debt, a term loan or convertible notes? Our latest debt story, dated Jun 10, 2026: "Precision BioSciences extends Banc of California term loan". Precision BioSciences has moved the maturity of its Banc of California term loan from June 30, 2027 to December 31, 2029. The company used $65.8 million in operations in 2025 and ended 2024 with $85.9 million in cash and cash equivalents. [Source](https://aibio.space/news/precision-biosciences-extends-banc-california-term-loan/). ## Investor discussion: Precision BioSciences Members talk about Precision BioSciences (DTIL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Precision BioSciences, newest first. Each line links the filing it comes from. 1. 2025-11-12 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1357874/000162828025051369/pro-suppdraft1162025.htm) 2. 2025-03-26 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1357874/000095017025045420/2025.03.27_atm_pro_sup.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:DTIL on TradingView](https://www.tradingview.com/symbols/NASDAQ-DTIL/). ## SEC filings and registration - **SEC name**: Precision Biosciences Inc - **CIK**: 1357874 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: DTIL (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: May 21 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 302 EAST PETTIGREW STREET, DURHAM, NC, 27701 - **Phone**: 919-314-5512 - **Shares outstanding**: 27,601,554 as of 2026-08-03 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1357874/000162828026058512/dtil-20260824.htm) filed 2026-08-24 - [10-Q](https://www.sec.gov/Archives/edgar/data/1357874/000162828026053837/dtil-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1357874/000162828026053836/dtil-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1357874/000162828026049665/dtil-20260723.htm) filed 2026-07-27 - [8-K](https://www.sec.gov/Archives/edgar/data/1357874/000162828026046340/dtil-20260701.htm) filed 2026-07-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1357874/000162828026043526/dtil-20260610.htm) filed 2026-06-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1357874/000162828026038307/dtil-20260527.htm) filed 2026-05-27 - [8-K](https://www.sec.gov/Archives/edgar/data/1357874/000162828026038220/dtil-20260521.htm) filed 2026-05-26 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001357874), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Precision BioSciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DTIL, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Precision BioSciences, Inc. - **Ticker**: DTIL - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US74019P2074 - **Other listed symbols**: GETTEX:PBS0 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-DTIL/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/precision-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Precision BioSciences (DTIL) news: offering", 2026-10-31, https://aibio.space/companies/precision-biosciences/